Semaglutide, sold under the trade names Wegovy®, Ozempic®, and Rybelsus®, is a safe GLP-1 drug that is only available with a doctor's prescription.
This ground-breaking drug is now available in Bonita Springs, Florida.
Semaglutide Is A Big Deal.
In America, around 70% of people are obese or overweight. Being overweight or obese is a serious health issue that is associated with a higher chance of developing several cancers as well as some of the leading causes of death, including heart disease, stroke, and diabetes.
A 5% to 10% weight loss with diet and exercise in adults who were obese or overweight has been associated with a lower risk of cardiovascular disease.
Semaglutide imitates the hormone glucagon-like peptide-1 (GLP-1), which has an impact on the brain regions in charge of controlling appetite and calorie intake. The medication dose must be increased gradually over 16 to 20 weeks to 2.4 mg once weekly in order to reduce gastrointestinal side effects.
Wegovy should not be used in combination with any other semaglutide-containing products, GLP-1 receptor agonists, or other weight-loss drugs, including prescription, over-the-counter, and herbal items. Wegovy has not been tested in patients who have had pancreatitis in the past.
Wegovy's effectiveness and safety were investigated over the course of four 68-week trials. The fourth study was a randomized, double-blind, placebo-controlled withdrawal trial in which patients taking Wegovy had the option of continuing their medication or switching to a placebo.
The first three studies were randomized, double-blind, placebo-controlled trials (including dose increases every 16 weeks). In these four studies, more than 2,600 people received the medication semaglutide (Wegovy) for up to 68 weeks, while more than 1,500 patients received a placebo.
The largest placebo-controlled study included individuals without diabetes as participants. At the start of the investigation, the patients' average age was 46, and 74% of them were female. The average weight was 231 pounds, and the body mass index (BMI) was 38 kg/m2 (105 kg).
Those who got Wegovy lost an average of 12.4% of their starting weight compared to those who received a placebo.
Those with type 2 diabetes took part in a different trial. At a median age of 55, the population was mostly made up of women (51%).
The average body weight was 220 pounds, and the body mass index (BMI) was 36 kg/m2 (100 kg). In this trial, people who took Wegovy dropped 6.2% of their initial weight compared to those who received a placebo.
With the new FDA-approved, doctor-prescribed weight-loss medication Semaglutide, which is now accessible to residents of Bonita Springs, Florida, you may take control of your weight troubles.